- Investor's Business Daily•16 hours ago
Endo agreed to a 10-year settlement with the FTC on Monday, resolving a suit that alleges Endo paid Allergan to prevent it from launching a generic.
- Investopedia•18 hours ago
Endo Pharmaceuticals agrees to abandon "pay-for-delay." Allergan and Teva move lower in sympathy.
- Reuters•18 hours ago
The U.S. Federal Trade Commission said on Monday it had settled allegations that Endo Pharmaceuticals violated antitrust law when it agreed to pay rivals Watson Laboratories and Impax to delay introducing generic versions of two painkillers. The FTC filed charges against Watson, and Allergan Plc , accusing it of breaking the law by reaching an agreement with Endo to block a generic competitor for the local anesthetic Lidoderm. The FTC also filed an administrative complaint against Impax, saying it reached an illegal agreement with Endo in 2010 to prevent Impax from marketing a generic copy of Endo's painkiller Opana ER.
AGN : Summary for Allergan plc Ordinary Shares - Yahoo Finance
Allergan plc (AGN)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||211.11 - 218.08|
|52 Week Range||184.50 - 301.32|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.02|
|Dividend & Yield||2.80 (1.31%)|
|1y Target Est||N/A|